| Original language | English |
|---|---|
| Pages (from-to) | 1-90 |
| Number of pages | 90 |
| Journal | Health Technology Assessment |
| Volume | 27 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 27 Jun 2023 |
Bibliographical note
Funding Information:Funding: This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in ealth H eT chnology Assessment Vol. 27, No. 9. See the NIHR Journals Library website for further project information.
Funding Information:
This project is funded by the NIHR Health Technology Assessment (HTA) programme (study reference 13/34/64). Saul N Faust is part-funded by the Southampton NIHR Biomedical Research Centre. We are very grateful to both the Trial Steering Committee [Elaine Hay (chairperson), Robbie Foy, Reuben Ogollah and Kirsty Samuel (PPI representative)] and the DMSC [Sally Kerry (chairperson), Chris Griffiths, Andrew Hayward and Peter Landman (PPI representative)] for their support and advice. Zöe Morrice (student placement) contributed to the qualitative study. This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 27, No. 9. See the NIHR Journals Library website for further project information.
Funding Information:
The research reported in this issue of the journal was funded by the HTA programme as project number 13/34/64. The contractual start date was in July 2016. The draft report began editorial review in April 2021 and was accepted for publication in February 2022. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.
Funding Information:
?eclared competing interests of authors: Theo Verheij reports grants from the European Union and The Netherlands Organisation for Health Research and ? evelopment during the conduct of the study, and grants from Abbott Laboratories (Chicago, IL, USA), Becton, ?ickinson and Company (Franklin Lakes, NJ, USA), bioMérieux (Marcy-l’C? toile, France) and Janssen Pharmaceuticals (Beerse, Belgium) outside the submitted work. Paul Little was a member of the National Institute for Health and Care Research (NIHR) Journals Library Board (2011–17). Kerenza Hood is a member of the NIHR Health Technology Assessment (HTA) General Committee and the HTA Funding Strategy Group. Saul N Faust is a member of the RECOVERY Trial Steering Committee, the HTA Commissioning Board and other NIHR national groups, and reports funds to his institution but no personal payments for multiple commercial contracts, advisory board participation and presentations [Pfizer (New York, NY, USA), AstraZeneca (Cambridge, UK), MedImmune (Gaithersburg, M? , USA), Sanofi (Paris, France), CSL Seqirus (Maidenhead, UK) and Merck Group (? armstadt, Germany)]. Robert C Read reports that he is NIHR Biomedical Research Centre ?irec-tor and editor-in-chief of Journal of Infection. James Raftery reports membership of the NIHR HTA and Efficacy and Mechanism Evaluation Editorial Board in a paid role. Nick A Francis reports a research grant from Synairgen plc (Southampton, UK) for COVI?-19 research, non-financial support for a NIHR HTA trial on reducing antibiotics for COP? from Abbott Laboratories, a speaker’s fee from Abbott Laboratories, and stock/stock options from Abbott Laboratories and Synairgen plc.
Publisher Copyright:
© 2023 Little et al.